VOAGE S TAB 15 S

About

Sitagliptin is an oral antidiabetic drug from the dipeptidyl peptidase-4 (DPP-4) inhibitor class, indicated for the treatment of type 2 diabetes mellitus. It works by selectively inhibiting the enzyme DPP-4, which normally breaks down the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing the rapid inactivation of these incretins, sitagliptin increases their levels, leading to enhanced glucose-dependent insulin release from pancreatic beta cells and reduced glucagon secretion from pancreatic alpha cells.

This mechanism helps to lower both fasting and post-meal blood glucose concentrations, improving overall glycemic control. Sitagliptin is often used as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• As monotherapy or combination therapy.
• When lifestyle interventions are insufficient.

Directions For Use

Take this medication orally once daily, with or without food, as directed by your healthcare provider.

Benefits

• Effectively lowers blood glucose levels.
• Reduces HbA1c without causing weight gain.
• Low risk of hypoglycemia when used alone.
• Enhances the body's natural ability to lower blood sugar.
• Improves both fasting and post-meal glucose.
• Generally well-tolerated with once-daily dosing.

Side Effects

• Headache
• Nasopharyngitis
• Upper respiratory tract infection
• Diarrhea
• Nausea
• Abdominal pain
• Arthralgia
• Back pain
• Hypoglycemia (especially with sulfonylureas)
• Pancreatitis (rare)
• Allergic reactions (rash, urticaria)
• Bullous pemphigoid (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake can affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy due to limited human data. Use only if potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if sitagliptin is excreted in human milk. A decision should be made whether to discontinue nursing or the drug.
• Liver - No dose adjustment is typically required for mild to moderate hepatic impairment. Use with caution in severe impairment.
• Kidney - Dose adjustment is required for patients with moderate to severe renal impairment and end-stage renal disease.
• Lung - No specific contraindications or significant concerns related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.